EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Single-cell and spatial profiling highlights TB-induced myofibroblasts as drivers of lung pathology

Ian M. Mbano, Nuo Liu, Marc H. Wadsworth, Mark J. Chambers, Thabo Mpotje, Osaretin E. Asowata, Sarah K. Nyquist, Kievershen Nargan, Duran Ramsuran, Farina Karim, Travis K. Hughes, Joshua D. Bromley, Robert Krause, Threnesan Naidoo, Liku B. Tezera, Michaela T. Reichmann, Sharie Keanne Ganchua, Henrik N. Kløverpris, Kaylesh J. Dullabh, Rajhmun Madansein, Sergio Triana, Adrie J.C. Steyn, Bonnie Berger, Mohlopheni J. Marakalala, Gabriele Pollara, Sarah M. Fortune, JoAnne L. Flynn, Paul T. Elkington, Alex K. Shalek, Alasdair Leslie

Journal of Experimental Medicine · 2026-03-02 · 223 (3)

DOI: 10.1084/jem.20251067 ↗
AbstractBibliografische Angaben

Abstract

Tuberculosis (TB) typically causes lung destruction and fibrosis, leading to ∼1.3 million deaths annually. The cellular drivers of human TB immunopathology remain poorly defined. We performed single-cell RNA sequencing and spatial transcriptomics on lung tissues from TB-infected and TB-negative individuals, identifying 30 distinct immune, parenchymal, and stromal cell subsets. Several were linked to TB pathology and corroborated through immunohistochemistry, flow cytometry, and independent human datasets. Fibroblasts were identified as major drivers in both active TB granuloma and TB-diseased lung tissue. In particular, the MMP1+CXCL5+ fibroblast subset, expressing a myofibroblast-like gene signature, was associated with severe disease and higher bacterial burden in nonhuman primate granulomas. Network analyses revealed cross talk between MMP1+CXCL5+ fibroblasts and SPP1+ macrophages within the granuloma cuff, which has been reported in other disease contexts, and may play an important role in TB immunopathology. Our findings highlight previously unappreciated cell populations and potential targets for novel TB therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →